公开(公告)号：US20120071399A1

公开(公告)日：2012-03-22

申请号：US13170634

申请日：2011-06-28

申请人： JOSHUA RABBANI ,  JAMES J. DONEGAN ,  XIAOFENG LI

发明人： JOSHUA RABBANI ,  JAMES J. DONEGAN ,  XIAOFENG LI

IPC分类号： A61K38/10 ,  C07K7/08 ,  C07K19/00 ,  C12N5/00 ,  A61K38/08 ,  A61P19/10 ,  A61P19/08 ,  A61P35/00 ,  A61P3/10 ,  A61P17/14 ,  A61P13/12 ,  A61P19/06 ,  A61P9/12 ,  A61P19/02 ,  A61P9/10 ,  A61P9/00 ,  A61P3/04 ,  C07K7/06

CPC分类号： A61K38/1709 ,  A61K38/08 ,  A61K38/10 ,  C07K14/47 ,  C07K14/51 ,  C07K14/705 ,  C07K14/71

摘要： Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213. Also provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being sulfated, where the composition is capable of inhibiting sclerostin binding to an LRP. Further provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being post-translationally sulfated, where the composition is capable of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner. Additionally provided is a method of enhancing a Wnt signaling pathway comprising contacting an LRP5/6 receptor in the Wnt signaling pathway with either of the above-described compositions that comprise a sequence of a sclerostin fragment or is capable of inhibiting sclerostin binding to an LRP, where the tyrosine or tyrosine analog is not sulfated, in a manner sufficient to enhance the Wnt signaling pathway. Further provided is a method of treating a subject having a disease exacerbated by inhibition of a Wnt signaling pathway comprising administering either of the above-described compositions that comprise a sequence of a sclerostin fragment or is capable of inhibiting sclerostin binding to an LRP, where the tyrosine or tyrosine analog is not sulfated, to the subject in a manner sufficient to reduce the inhibition of the Wnt signaling pathway. Also, a method of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner is provided. The method comprises adding the above-described composition that is capable of inhibiting binding of a protein ligand to its binding partner to the protein ligand and its binding partner in a manner sufficient to inhibit binding of the protein ligand to its binding partner.

公开(公告)号：US20160317616A1

公开(公告)日：2016-11-03

申请号：US15195017

申请日：2016-06-28

申请人： JOSHUA RABBANI ,  XIAOFENG LI ,  JAMES J. DONEGAN

发明人： JOSHUA RABBANI ,  XIAOFENG LI ,  JAMES J. DONEGAN

IPC分类号： A61K38/17 ,  A61K38/08 ,  C07K14/47 ,  A61K38/10

CPC分类号： A61K38/1709 ,  A61K38/08 ,  A61K38/10 ,  C07K14/47 ,  C07K14/51 ,  C07K14/705 ,  C07K14/71

摘要： Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213. Also provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being sulfated, where the composition is capable of inhibiting sclerostin binding to an LRP. Further provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being post-translationally sulfated, where the composition is capable of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner.

摘要翻译： 提供了包含包含氨基酸和/或氨基酸类似物的肽的组合物，其包含包含Tyr43或Tyr213的硬化蛋白片段的连续序列。 还提供了包含包含少于约75个氨基酸和/或氨基酸类似物的肽的组合物，其包含能够被硫酸化的氨基酸或氨基酸类似物，其中该组合物能够抑制与LRP结合的硬皮蛋白。 还提供了一种组合物，其包含包含小于约75个氨基酸和/或氨基酸类似物的肽，其包含能够翻译后硫酸化的氨基酸或氨基酸类似物，其中组合物能够抑制蛋白质配体的结合， 硫酸化位点到其结合配偶体。

公开(公告)号：US20120252007A1

公开(公告)日：2012-10-04

申请号：US13436174

申请日：2012-03-30

申请人： ELAZAR RABBANI ,  JAMES J. DONEGAN ,  DAKAI LIU

发明人： ELAZAR RABBANI ,  JAMES J. DONEGAN ,  DAKAI LIU

IPC分类号： G01N21/64

CPC分类号： C12Q1/6818 ,  C12Q1/6844 ,  C12Q1/6846 ,  C12Q1/6853 ,  C12Q1/6876 ,  C12Q1/707 ,  C12Q1/708 ,  C12Q2565/101 ,  C12Q2533/101

摘要： This invention provides for compositions for use in real time nucleic acid detection processes. Such real time nucleic acid detection processes are carried out with energy transfer elements attached to nucleic acid primers, nucleotides, nucleic acid probes or nucleic acid binding agents. Real time nucleic acid detection allows for the qualitative or quantitative detection or determination of single-stranded or double-stranded nucleic acids of interest in a sample. Other processes are provided by this invention including processes for removing a portion of a homopolymeric sequence, e.g., poly A sequence or tail, from an analyte or library of analytes. Compositions useful in carrying out such removal processes are also described and provided. Paneling and multiplex analyses of more than one nucleic acid analyte using one sample are also provided.

摘要翻译： 本发明提供用于实时核酸检测过程的组合物。 这种实时核酸检测方法是用连接于核酸引物，核苷酸，核酸探针或核酸结合剂的能量转移元件进行的。 实时核酸检测允许定性或定量检测或测定样品中感兴趣的单链或双链核酸。 本发明提供了其它方法，包括从被分析物或分析物库中除去一部分均聚物序列，例如聚A序列或尾部的方法。 还描述和提供了用于进行这种去除方法的组合物。 还提供了使用一个样品的多于一种核酸分析物的镶板和多重分析。

公开(公告)号：US20150140004A1

公开(公告)日：2015-05-21

申请号：US14572061

申请日：2014-12-16

申请人： MICHAEL C. MULLENIX ,  ROBERT ELLIOT ZIPKIN ,  JEFFREY KROLL ADAMS ,  WAYNE FORREST PATTON ,  JAMES J. DONEGAN

发明人： MICHAEL C. MULLENIX ,  ROBERT ELLIOT ZIPKIN ,  JEFFREY KROLL ADAMS ,  WAYNE FORREST PATTON ,  JAMES J. DONEGAN

IPC分类号： C07K16/18

CPC分类号： G01N33/92 ,  C07J9/00 ,  C07J43/003 ,  C07K16/18 ,  C07K16/44 ,  C07K2317/21 ,  G01N33/5308 ,  G01N33/56966 ,  G01N2800/2835 ,  G01N2800/285 ,  G01N2800/52

摘要： Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. A method of detecting an enzyme or enzymes utilized in phase II drug metabolism is also provided. Also, a method of detecting an enzyme that synthesizes 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Further provided is a method of evaluating progression of multiple sclerosis in a patient. Also provided is a method of determining whether a treatment for multiple sclerosis in a patient is effective. Further, a method of evaluating progression of Huntington's disease in a patient is provided. Additionally provided is a method of determining whether a treatment for Huntington's disease in a patient is effective.

摘要翻译： 提供了22-羟基胆固醇，24S-羟基胆固醇，25-羟基胆固醇，26-羟基胆固醇或27-羟基胆固醇的衍生物。 还提供了与上述衍生物结合的蛋白质。 进一步提供了包含特异性结合22-羟基胆固醇，24S-羟基胆固醇，25-羟基胆固醇，26-羟基胆固醇或27-羟基胆固醇的抗体的抗体组合物。 此外，提供了制备特异性结合22-羟基胆固醇，24S-羟基胆固醇，25-羟基胆固醇，26-羟基胆固醇或27-羟基胆固醇的抗体的方法。 此外，提供了测定22-羟基胆固醇，24S-羟基胆固醇，25-羟基胆固醇，26-羟基胆固醇或27-羟基胆固醇的方法。 另外提供了用于检测22-羟基胆固醇，24S-羟基胆固醇，25-羟基胆固醇，26-羟基胆固醇或27-羟基胆固醇的试剂盒。 还提供了检测在II期药物代谢中使用的酶或酶的方法。 此外，提供了检测合成22-羟基胆固醇，24S-羟基胆固醇，25-羟基胆固醇，26-羟基胆固醇或27-羟基胆固醇的酶的方法。 进一步提供评估患者多发性硬化症进展的方法。 还提供了确定患者多发性硬化症的治疗是否有效的方法。 此外，提供了评价患者中亨廷顿病进展的方法。 另外提供了一种确定患者亨廷顿氏病的治疗是否有效的方法。